

検査内容変更のお知らせ

謹啓 時下ますますご清栄のこととお慶び申し上げます。
平素は格別のご高配を賜り厚くお礼申し上げます。
この度、下記検査項目におきまして、検査内容の変更をご案内いたします。
健康と医療の未来に貢献すべく、より良い検査サービスのご提供に努めてまいります。
謹白

記

■ 変更日 2023年7月7日（金）ご依頼分より

■ 変更項目

	項目コード（迅速細菌）	検査項目	
一般細菌	50020A1（5282N）	感受性検査 （標準）	口腔、気道または呼吸器からの検体
	50023A1（5283N）		消化管からの検体
	50026A1（5284N）		泌尿器または生殖器からの検体
	50029A1（5285N）		血液または穿刺液
	50032A1（5286N）		その他の部位からの検体
	50035A1（5287N）	感受性検査 （オプション）	口腔、気道または呼吸器からの検体
	50038A1（5288N）		消化管からの検体
	50041A1（5289N）		泌尿器または生殖器からの検体
	50044A1（5290N）		血液または穿刺液
	50047A1（5291N）		その他の部位からの検体

■ お問い合わせ先

細菌検査インフォメーション：050-2000-5742



● 感受性検査（一般細菌）

臨床・検査標準協会（CLSI：Clinical and Laboratory Standards Institute）の「抗菌薬感受性試験のための標準検査法—第30版」などへの改訂に伴い、判定基準、薬剤感受性標準セットを変更させていただきます。

■ 変更内容

変更内容	新	現
判定基準	CLSI M100-S30	CLSI M100-S22
薬剤感受性標準セット	下記参照	

薬剤感受性標準セット

系統/略語/一般名(慣用名)	薬剤	菌群	フトウ球菌	(グラム陰性桿菌)	バチルス菌	リステリア菌	ノカルジア菌	モラクセラ	肺炎球菌	連鎖球菌	腸球菌	ヘモフィルス	グラム陰性桿菌	緑膿菌	アシネトバクター	マルトフィリア	バクテロイデア	セハシア	その他の非発酵菌	(グラム陰性桿菌)	カンピロバクター	ビブリオ	嫌気性菌	淋菌
			●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
ペニシリン系 (penicillins)	PCG	ベンジルペニシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	MPIC	オキサリリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	ABPC	アンピシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	PIPC	ピペラシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
セフェム系 (cephems)	CEZ	セファゾリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CTM	セフォチアム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CXM	セフロキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CTX	セフトキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CMX	セフトキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CAZ	セフトジニム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CTRX	セフトリアキソン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CFPM	セフェピム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CMZ	セフメタゾール	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	COL	セファクロル	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CFX	セフィキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CPDX-PR	セフトキシム-プロキセチル	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CDTR-PI	セフトレン-ピロキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CFDN	セフジニム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
FMOX	フロモキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎	
LMOX	ラタモキシム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎	
カルバペナム系 (carbapenems)	IPM/CS	イミペナム/シラスタチン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	MEPM	メロペナム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	DRPM	ドリベナム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
モノバクタム系 (monobactams)	AZT	アストレオナム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎	
β-ラクタマーゼ阻害剤 (β-lactamase inhibitors)	CVA/AMPC	クラファン酸/アモキシシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	SBT/ABPC	スルバクタム/アンピシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	SBT/CPZ	スルバクタム/セフォヘラソン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	TAZ/PIPC	タゾバクタム/ピペラシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
アミノグリコシド系 (aminoglycosides)	GM	ゲンタマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	AMK	アミカシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	TOB	トブラマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
マクロライド系 (macrolides)	ABK	アルベカシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CAM	クラリスロマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	EM	エリスロマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
テトラサイクリン系 (tetracyclines)	AZM	アジスロマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	MNO	ミノサイクリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
リンコマイシン系 (lincosamides)	TC	テトラサイクリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CLDM	クリンダマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
キノロン系 (quinolones)	LVFX	レボフロキサシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	OPFX	シプロフロキサシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	MFLX	モキシフロキサシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	GRNX	ガレノキサシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
グリコペプチド系 (glycopeptides)	STFX	シタフロキサシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	VCM	バンコマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	▲
	TEIC	テイコプラネン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	▲
その他の系 (miscellaneous antibacterial agents)	ST	スルファメトキサゾール/トリメトプリム	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	FOM	ホスホマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	CP	クロラムフェニコール	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	MNZ	メトロニダゾール	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	RFP	リファンピシリン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
	LZD	リネゾリド	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎
DAP	ダプトマイシン	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	◎	

▲：VCMは*C. difficile*検出時報告します。

◎：淋菌はディスク拡散法を用いて検査します。

● 参考文献

CLSI M100 : Performance Standards for Antimicrobial Susceptibility Testing 30th Edition, 2020. 他